top of page

Gender-affirming Hormones

EXPECTED EFFECTS & TIME COURSE

Hormones are prescription medicines. The following is the expectation of a usual dose. These information is for reference only. Please consult your doctor for details.

  • The degree and rate of various effects is dependent on the dose and route of administration, as well as factors such as age, body habitus, lifestyle, genetics, etc.

  • If a lower dose is used, generally more time is needed for the onset of each effect. The time of onset is depedent of the dose. If a lower dose of hormoens is used in long term, the maximal effects of each aspect is expected to be reached, and can be prevented by stopping the hormones. Please consult your doctor for details.

The content below is referenced with the Standards of Care for the Health of Transgender and Gender Diverse People published by the World Professional Association for Transgender Health.

feminizing.png

ESTROGEN & ANDROGEN BLOCKER - EXPECTED EFFECTS & TIME COURSE

  • Bold: Irreversible (The effect will not be reversed if hormones are stopped).

  • Underline: Variable

  • Remaining: Reversible (The effect will be reversed if hormones are stopped).

Effect

Onset

Expected maximal effect

Breast development

3-6 months

1-2 years

Skin softens, ↓ oil production

3-6 months

Variable / unknown

Body fat redistribution

3-6 months

2-5 years

↓ Muscle mass & muscle strength

3-6 months

1-2 years

↓ Growth of facial hair & body hair

6-12 months

>3 years

↓ Androgenic alopecia

1-3 months

Variable

↓ Spontaneous erections

1-3 months

3-6 months

↓ Sperm production

Variable / unknown

2 years

↓ Testicular volume

3-6 months

Variable

↓ Libido

1-3 months

Variable / unknown

ESTROGEN & ANDROGEN BLOCKER - POTENIAL RISKS

  • UnderlinedWith clinical significance (Has meaningful impact and/or practical importance on health).

  • *Only applicable when using spironolactone as androgen blocker.

  • ^Only applicaable when using cyproterone as androgen blocker.

Risk level

Potential risk

🔔🔔 Likely increased risk

  • Venous thromboembolism

  • Infertility

  • Hypertrigyceridemia

  • Weight gain

  • Hyperkalemia*

🔔 Only if one has existing risk factors, will have likely increased risk

  • Cardiovascular & cerebrovascular diseases

  • Polyuria/dehydration*

  • Meningioma^

  • Cholelithiasis

🔔 Possible increased risk

  • Hypertension

  • Erectile dysfunction

🔔 Only if one has existing risk factors, will have possible increased risk

  • Type 2 diabetes

  • Low bone mass/osteoporosis

  • Hyperprolactinemia

No increased risk / inconclusive

  • Breast cancer

  • Prostate cancer

2.png

TESTOSTERONE - EXPECTED EFFECTS & TIME COURSE

  • Bold: Irreversible (The effect will not be reversed if hormones are stopped).

  • Remaining: Reversible (The effect will be reversed if hormones are stopped).

Effect

Onset

Expected maximal effect

Deepening of the voice

1-6 months

1-2 years

Acne, ↑ oil production on skin

1-6 months

1-2 years

Body fat redistribution

1-6 months

2-5 years

↑ muscle mass & muscle strength

6-12 months

2-5 years

Growth of facial hair & body hair

6-12 months

>5 years

Androgenic alopecia

6-12 months

>5 years

Cessation of menstruation

1-6 months

1-2 years

Vaginal atrophy

1-6 months

1-2 years

Clitoral enlargement

1-6 months

1-2 years

TESTOSTERONE - POTENITAL RISKS

  • Underlined: With clinical significance (Has meaningful impact and/or practical importance on health).

Risk level

Potential risk

🔔🔔 Likely increased risk

  • Polycythemia

  • Infertility

  • Acne

  • Androgenic alopecia

  • Hypertension

  • Sleep apnea

  • Weight gain

  • ↓ HDL, ↑ LDL 

🔔 Only if one has existing risk factors, will have likely increased risk

  • Cardiovascular diseases

  • Hypertrigyceridemia

🔔 Possible increased risk

/

🔔 Only if one has existing risk factors, will have possible increased risk

  • Type 2 diabetes

  • Cerebrovascular diseases

No increased risk / inconclusive

  • Low bone mass / osteoporosis

  • Breast cancer

  • Cervical cancer

  • Uterine cancer

  • Ovarian cancer

bottom of page